| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CHRM3 |
| Uniprot No | P20309 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 253-492aa |
| 氨基酸序列 | RIYKETEKRTKELAGLQASGTEAETENFVHPTGSSRSCSSYELQQQSMKRSNRRKYGRCHFWFTTKSWKPSSEQMDQDHSSSDSWNNNDAAASLENSASSDEEDIGSETRAIYSIVLKLPGHSTILNSTKLPSSDNLQVPEEELGMVDLERKADKLQAQKSVDDGGSFPKSFSKLPIQLESAVDTAKTSDVNSSVGKSTATLPLSFKEATLAKRFALKTRSQITKRKRMSLVKEKKAAQT |
| 预测分子量 | 32.7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CHRM3重组蛋白的3篇代表性文献及其摘要概括：
1. **文献名称**：*"Expression and functional characterization of the human M3 muscarinic acetylcholine receptor in Saccharomyces cerevisiae"*
**作者**：Dowell, S.J. et al.
**摘要**：研究利用酵母系统重组表达人源CHRM3蛋白，验证其与G蛋白偶联的信号传导功能，并建立基于酵母的高通量药物筛选平台。
2. **文献名称**：*"Crystal structure of the M3 muscarinic acetylcholine receptor bound to a quinuclidinyl benzilate antagonist"*
**作者**：Kruse, A.C. et al.
**摘要**：通过重组表达技术获得CHRM3蛋白的晶体结构，解析其与拮抗剂结合的分子机制，为靶向药物设计提供结构基础。
3. **文献名称**：*"Reconstitution of the human M3 muscarinic receptor in lipid nanodiscs for NMR studies"*
**作者**：Maeda, S. et al.
**摘要**：开发了一种基于纳米脂盘(nanodisc)的重组CHRM3蛋白稳定化方法，结合核磁共振(NMR)技术研究其动态构象变化与信号转导机制。
4. **文献名称**：*"Targeted delivery of recombinant M3 muscarinic acetylcholine receptors to airway smooth muscle"*
**作者**：Walker, J.K.L. et al.
**摘要**：探索重组CHRM3蛋白在气道平滑肌细胞中的靶向递送策略，评估其在治疗哮喘等呼吸系统疾病中的潜在应用价值。
这些文献涵盖了CHRM3重组蛋白的表达系统开发、结构解析、功能研究及治疗应用方向。如需具体发表年份或期刊信息，可进一步补充查询。
**Background of CHRM3 Recombinant Protein**
The **muscarinic acetylcholine receptor M3 (CHRM3)** is a G protein-coupled receptor (GPCR) that binds acetylcholine, a key neurotransmitter in the parasympathetic nervous system. It is one of five muscarinic receptor subtypes (M1-M5) and is primarily coupled to Gq/11 proteins. Upon activation, CHRM3 triggers intracellular signaling cascades, including phospholipase C (PLC) activation, which leads to the release of calcium ions and modulation of various physiological processes.
CHRM3 is widely expressed in smooth muscles (e.g., gastrointestinal tract, bladder), exocrine glands (e.g., salivary, sweat glands), and the central nervous system. It plays critical roles in regulating smooth muscle contraction, glandular secretion, and cognitive functions. Dysregulation of CHRM3 is implicated in diseases such as asthma, overactive bladder, diabetes (via pancreatic β-cell insulin secretion), and neurological disorders.
**Recombinant CHRM3 protein** is engineered in vitro using heterologous expression systems (e.g., HEK293 or insect cells) to produce purified, functional receptor proteins for research. These systems allow precise control over post-translational modifications, ensuring structural and functional fidelity. The recombinant protein often includes tags (e.g., His, FLAG) for simplified purification and detection.
Studying recombinant CHRM3 enables detailed mechanistic investigations, such as ligand-binding assays, receptor activation kinetics, and interactions with downstream effectors. It also aids in drug discovery, particularly for designing subtype-specific agonists/antagonists to minimize off-target effects. Additionally, engineered mutants of recombinant CHRM3 help identify residues critical for ligand binding or signaling, advancing the understanding of GPCR biology and therapeutic targeting.
In summary, CHRM3 recombinant protein serves as a vital tool for dissecting the receptor’s role in health and disease, bridging molecular insights with translational applications.
×
